Hospira HSP 0% (HSP), the injectable generic drug maker Pfizer PFE -0.66% (PFE) is buying for $90 a share, is making its biggest foray yet into the business of cheaper “generic” biologic drugs this week, launching the biosimilar to the pricey autoimmune drug Remicade in Europe.
Hospira will begin selling Inflectra, also known as infliximab, as a treatment for rheumatoid arthritis, Crohn’s disease and other autoimmune disorders in Germany, France, Spain and Italy, markets where Merck (MRK) tallied sales valued at more than $2 billion globally in 2013. Johnson & Johnson JNJ +1.2% (JNJ) sells Remicade in the U.S. where it costs more than $20,000 a year per patient.
Help employers find you! Check out all the jobs and post your resume.
